Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × polatuzumab vedotin × Clear all

Phase

Phase 1/2 2 Phase 2 1

Status

Recruiting 16 Not yet recruiting 7 Active not recruiting 6 Withdrawn 1 Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 53 Radiotherapy 50 Paclitaxel 43 Cisplatin 41 Gemcitabine 40 Cyclophosphamide 39 Carboplatin 39 Docetaxel 33 Dexamethasone 33 Nivolumab 31 Fluorouracil 29 Bevacizumab 29 durvalumab 28 Oxaliplatin 27 Magnetic Resonance Spectroscopy 25 Rituximab 24 Leucovorin 23 Pemetrexed 22 Capecitabine 21 Drug Therapy 20 Doxorubicin 19 atezolizumab 17 Radiosurgery 17 Cytarabine 17 Radiation 16 Prednisone 16 Etoposide 16 Bortezomib 16 fludarabine 13 Lenalidomide 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04535102 2022-05-09

POLA+BR for Relapsed or Refractory DLBCL

University of Colorado, Denver

Phase 2 Withdrawn

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡